Correction: Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells (Cancer Research (2006) 66 (9270–9280) DOI: 10.1158/0008-5472.CAN-06-1758);Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells

Cancer Research

Volumn 66, Issue 18, 2006, Pages 9270-9280

  Cai, Dongpo ^a,b   Latham Jr , Vaughan M ^a,b   Zhang, Xinxin ^a,b,c   Shapiro, Geoffrey I ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 9; FLAVOPIRIDOL; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; ENDOREDUPLICATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33749503799     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-19-3524     Document Type: Erratum

References (42)

1. Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 2002;8:S32-7.
2. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
3. Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem 2002;277:33922-9.
4. Cisek LJ, Corden JL. Phosphorylation of RNA polymerase by the murine homologue of the cell-cycle control protein cdc2. Nature 1989;339:679-84.
5. 2 roles for cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 2001;21:2755-66.
6. Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997;15:2991-7.
7. Chen YNP, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A 1999;96:4325-9.
8. Chen W, Lee J, Cho SY, Fine HA. Proteasome-mediated destruction of the cyclin A/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res 2004;64:3949-57.
9. Tetsu O, McCormick F. Proliferation of cancer cells despite cdk2 inhibition. Cancer Cell 2003;3:233-45.
10. 1-S phase transition. Nat Cell Biol 2005;7:831-6.
11. Garriga J, Grana X. Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene 2004;337:15-23.
12. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:research 0041.1-11.
13. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered as a pharmacologically-derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia [abstract 341]. Blood 2004;104:101a.
14. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005;106:2513-9.
15. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci U S A 1995;92:6289-93.
16. Park YB, Park MJ, Kimura K, Shimizu K, Lee SH, Yokota J. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet 2002;133:105-11.
17. Mitsudomi T, Steinberg SM, Nau MM, et al. p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992;7:171-80.
18. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF, Minna JD. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 2004;64:3137-43.
19. Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006;124:1283-98.
20. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003;77:8957-61.
21. Jiang J, Matranga CB, Cai D, et al. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res 2003;63:7410-22.
22. Matranga CB, Shapiro GI. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 2002;62:1707-17.
23. Palancade B, Bensaude O. Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur J Biochem 2003;270:3859-70.
24. Somesh BP, Reid J, Liu WF, et al. Multiple mechanisms confining RNA polymerase II ubiquitylation to polymerases undergoing transcriptional arrest. Cell 2005;121:913-23.
25. Chao SH, Price DH. Flavopiridol inactivates p-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276:31793-9.
26. 1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
27. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003;13:1775-85.
28. Ortega S, Prieto I, Odajima J, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003;35:25-31.
29. Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004;6:565-76.
30. Itzhaki JE, Gilbert CS, Porter AC. Construction by gene targeting in human cells of a "conditional" CDC2 mutant that rereplicates its DNA. Nat Genet 1997;15:258-65.
31. Litvak V, Argov R, Dahan N, et al. Mitotic phosphorylation of the peripheral Golgi protein Nir2 by Cdk1 provides a docking mechanism for Plk1 and affects cytokinesis completion. Mol Cell 2004;14:319-30.
32. Payton M, Chung G, Yakowec P, et al. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res 2006;66:4299-308.
33. Ma Y, Cress D, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F-1 and repression of Mcl-1. Mol Cancer Ther 2003;2:73-81.
34. Ma Y, Freeman SN, Cress WD. E2F4 deficiency promotes drug-induced apoptosis. Cancer Biol Ther 2004;3:1262-9.
35. Zhu Y, Alvarez C, Doll R, et al. Intra-S-phase checkpoint activation by direct CDK2 inhibition. Mol Cell Biol 2004;24:6268-77.
36. Maude SL, Enders GH. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Res 2005;65:780-6.
37. Bregman DB, Pestell RG, Kidd VJ. Cell cycle regulation and RNA polymerase II. Front Biosci 2000;5:D244-57.
38. Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002;190:160-9.
39. Whittaker SR, Walton MI, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004;64:262-72.
40. MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005;65:5399-407.
41. Cai D, Byth KF, Shapiro GI. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res 2006;66:435-44.
42. Dong F, Guo W, Zhang L, et al. Downregulation of XIAP and Induction of Apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells. Cancer Biol Ther 2006;5:165-70.